ORYZON receives approval in France to start ETHERAL: a Phase IIa clinical trial in Alzheimer’s Disease with ORY-2001

MADRID, SPAIN and CAMBRIDGE MA.

• Approval has been granted by the French Medicines Agency (ANSM)

• The trial received approval from the Spanish Medicines Agency in April

• ETHERAL is the second Phase II clinical trial in CNS with the drug

Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, has announced today that it has received the approval from the Agence Nacional du Securité du Medicament et des Produits de Santé (ANSM), the French Medicines Agency, to conduct a Phase IIa trial with ORY-2001 in patients with mild and moderate Alzheimer’s disease.

Click here to see the full Press Release